EyeCRO are Experts in preclinical efficacy studies in ophthalmic retinopathy, pharmacokinetics, both in vivo and in vitro for clinical and precise formulation services and trial batteries. EyeCRO is a preclinical ophthalmic research organization focused on studies in retina preclinical efficacy, oxygen-induced retinopathy, and ophthalmic pharmacokinetics for clinical and precise formulation services and trial batteries. EyeCRO is a preclinical ophthalmic research organization focused on studies in Laser CNV, Retina preclinical efficacy, and Ophthalmic toxicology for clinical and precise formulation services.

Web developed by Josh Bolinger website design

The Global Leader in Preclinical Ophthalmic Research

MiDROPS™

The EyeCRO Microemulsion Drug Ocular Penetration System (MiDROPS™) is a transformative technology for the development of eyedrop formulations.  This patented platform allows for the preparation and delivery of lipophilic agents to tissues in both the front and back of the eye.  MiDROPS™ are prepared using materials already approved by the US Food and Drug Administration for use in ophthalmic products, and by nature are intrinsically thermo-stable.

In-Vivo

EyeCRO provides numerous in-vivo research models to enable directed and meaningful preclinical drug discovery and development programs. EyeCRO also has extensive experience in various routes of administration and can customize studies depending on your needs. One of the main advantages in working with EyeCRO is our ability to be flexible.

Scientist receives $4.9 million CIRM grant to advance work in retinitis pigmentosa

Shaomei Wang, MD, PhD, a research scientist in the Eye Program at the Cedars-Sinai Board of … Read More

Amarantus Announces the Presentation of Data Showing MANF”s Positive Effect on Retinal Function at Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Amarantus BioScience Holdings, Inc. announced the presentation of positive preclinical data for MANF … Read More

More News

May 28th, 2015 at 7:08pm
RT @iarons: What will Gene Therapy & Stem Cell Treatment Cost & How Will We Pay for It? See: https://t.co/Ak0NmWa7jW $ONCE $OCAT $AAVL @Oph
May 27th, 2015 at 10:28am
Diabetic Retinopathy will require agents which inhibit more than just VEGF. http://t.co/tFyPcSxoit
May 26th, 2015 at 10:44am
RT @UMKelloggEye: Rare Mutation Causes Vitamin A Deficiency and Eye Deformities http://t.co/nKbyMaY1sw
May 22nd, 2015 at 11:06pm
RT @OphthTimes: Isarna Announces Orphan Drug Designation in the European Union for ISTH0036 to Treat Advanced-Stage Glaucoma http://t.co/L…
Ophthalmic Contract Research